Active	Status	Sponsor type	Region	Phase	Filter
1 Active 5 Inactive 6 All	Not yet recruiting Recruiting Enrolling by invitation Active, not recruiting Available No longer recruiting	Industry lead sponsor Industry collaborator Coop Other Show only owner-sponsored trials	US Canada Japan Europe RoW	N/A 1 2 3 4	Highlight changes: « March » « 2025 » M T W T F S S 24 25 26 27 28 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 1 2 3 4 5 6   - « March » « 2025 » M T W T F S S 24 25 26 27 28 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 1 2 3 4 5 6   Show only changed items Enrollment:

Advanced Filters

1 Trials

Active Trials   

 

Export

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
levosimendan oral (TNX-103) / Orion Corp, Tenax Therap
NCT05983250: LEVosimendan to Improve Exercise Limitation in Patients with PH-HFpEF	Recruiting	3	230	Canada, US	TNX-103, Placebo	Tenax Therapeutics, Inc., Medpace, Inc., Northwestern University	Pulmonary Hypertension	05/26	05/28

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
levosimendan oral (TNX-103) / Orion Corp, Tenax Therap
NCT05983250: LEVosimendan to Improve Exercise Limitation in Patients with PH-HFpEF	Recruiting	3	230	Canada, US	TNX-103, Placebo	Tenax Therapeutics, Inc., Medpace, Inc., Northwestern University	Pulmonary Hypertension	05/26	05/28